We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Comprehensive Influenza and Respiratory Virus Testing Service Launched

By LabMedica International staff writers
Posted on 01 Sep 2009
Print article
A new suite of tests identifies 2009 Influenza A H1N1, additional influenza subtypes, and other common respiratory viruses, such as rhinovirus, respiratory syncytial virus (RSV), and human metapneumovirus (HMPV).

The suite of four tests was launched by ViraCor-IBT Laboratories (Lee's Summit, MO, USA) as part of its influenza and respiratory virus testing service. They include the xTAG Respiratory Viral Panel (RVP), which detects 12 common respiratory viruses; a ViraCor-IBT-developed test specifically designed to detect 2009 Influenza A H1N1; a test to help physicians distinguish between the Influenza A H1 and Influenza A H3 subtypes; and a test that identifies antiviral-resistant mutations of the 2009 Influenza A H1N1.

The new testing service offers physicians and laboratories several ordering options, including reflex testing, which allows ViraCor-IBT to perform a second test without having to contact the ordering physician. It provides fast, accurate results within 24 hours and will help physicians pinpoint the cause of an infection, reduce unnecessary use of antivirals, and improve patient care.

"Correctly diagnosing a respiratory viral infection from a patient's symptoms alone is very difficult because most respiratory viruses cause very similar symptoms. The only way to be certain which pathogen is causing the infection is to run a laboratory test,” said Steve Kleiboeker, Ph.D., CSO for the combined ViraCor-IBT Laboratories. "With the emergence of antiviral-resistant viruses and new pathogens such as the pandemic Influenza A H1N1, testing for respiratory viruses has never been more important.”

All of ViraCor-IBT's respiratory virus testing options became available on September 1, 2009, except the 2009 Influenza A H1N1 antiviral resistance test, which is expected to be available later in the month.

ViraCor Laboratories and IBT Laboratories (Lenexa, KS, USA) merged in June 2009 to form a specialty diagnostics laboratory. The combined company specializes in cellular, immunology, and allergy testing services as well as molecular assays that detect and monitor microbial pathogens.

Related Links:
ViraCor-IBT Laboratories
IBT Laboratories


New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.